Global Peripheral Decarboxylase Inhibitors Market Growth 2025-2031

The global Peripheral Decarboxylase Inhibitors market size is predicted to grow from US$ 1715 million in 2025 to US$ 2337 million in 2031; it is expected to grow at a CAGR of 5.3% from 2025 to 2031.

Peripheral Decarboxylase Inhibitors (PDIs) are a class of drugs that selectively inhibit the enzyme aromatic L-amino acid decarboxylase (AADC) in the peripheral nervous system. This enzyme is responsible for converting levodopa into dopamine before it reaches the brain. By inhibiting this peripheral conversion, PDIs help increase the amount of levodopa that crosses the blood-brain barrier, enhancing its effectiveness in treating Parkinson’s disease while reducing peripheral side effects such as nausea and low blood pressure. Common PDIs include carbidopa and benserazide, which are often combined with levodopa in Parkinson’s therapy.

United States market for Peripheral Decarboxylase Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Peripheral Decarboxylase Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Peripheral Decarboxylase Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Peripheral Decarboxylase Inhibitors players cover Amneal Pharmaceuticals, AbbVie, Roche, Roemmers SAICF, Organon Pharma, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LP Information, Inc. (LPI) ' newest research report, the “Peripheral Decarboxylase Inhibitors Industry Forecast” looks at past sales and reviews total world Peripheral Decarboxylase Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Peripheral Decarboxylase Inhibitors sales for 2025 through 2031. With Peripheral Decarboxylase Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peripheral Decarboxylase Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global Peripheral Decarboxylase Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Peripheral Decarboxylase Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Peripheral Decarboxylase Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peripheral Decarboxylase Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peripheral Decarboxylase Inhibitors.

This report presents a comprehensive overview, market shares, and growth opportunities of Peripheral Decarboxylase Inhibitors market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Dopamine
Carbidopa

Segmentation by Application:
Hospital
Retail Pharmacy
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Amneal Pharmaceuticals
AbbVie
Roche
Roemmers SAICF
Organon Pharma
Teva
Mayne Pharma
Shanghai Fuda
Sun Pharmaceutical
Psicofarma
Pfizer
Eastpharma
Apotex
Torrent Pharmaceuticals
Novartis

Key Questions Addressed in this Report

What is the 10-year outlook for the global Peripheral Decarboxylase Inhibitors market?

What factors are driving Peripheral Decarboxylase Inhibitors market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Peripheral Decarboxylase Inhibitors market opportunities vary by end market size?

How does Peripheral Decarboxylase Inhibitors break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.